Bioniche launches injection for varicose veins in the U.S

Jul 15 2005

Bioniche Life Sciences has announced that its Pharma Division has launched Sotradecol(R) Injection (Sodium Tetradecyl Sulfate Injection) in the United States.

Sotradecol is approved by the U.S. Food and Drug Administration (FDA) for the treatment of small, uncomplicated varicose veins of the lower extremities. It is used in sclerotherapy (non-surgical vein removal). An estimated 1.7 million patients undergo sclerotherapy each year in the U.S.

"We are excited to be launching Sotradecol," said Albert Beraldo, President & CEO of Bioniche Pharma Group Limited. "It is the only FDA- approved, currently available Sodium Tetradecyl Sulfate Injection in the U.S. market." There has been a nation-wide shortage of this medically necessary product, which phlebologists have indicated is a highly effective and safe sclerosant for small and large veins.

Graeme McRae, President & CEO of Bioniche Life Sciences Inc. added, "Our Pharma Division has been very successful in obtaining regulatory approval for a range of pharmaceuticals targeting key markets, such as Sotradecol. These strategic additions to our product portfolio continue to drive our revenue stream and support further investment in research and development to bring our proprietary technologies to commercialization."

Sotradecol will be available in two strengths - 1% and 3% - packaged in 2 ml vials. It can be ordered either directly through the Bioniche customer service line (1-888-258-4199) or through local distributors and/or wholesalers in both hospital and primary care sectors of the market.